{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 39,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a 3D molecular structure visualization.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/38",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "image",
      "text": "3D molecular structure",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc03226d-1a64-4332-803a-d6d682b0ddfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "list",
      "text": "Parallel lead clinical programs in ROS1-positive and ALK-positive NSCLC: 2023 operational focus on advancement of concurrent Phase 1/2 clinical trials; Preliminary data from dose-escalation portion of Phase 1/2 ARROS-1 study presented at EORTC-NCI-AACR 2022; Preliminary data update from ALKOVE-1 dose-escalation planned in 2H'23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1446b7ed-8e6d-4935-930f-868c4c6c6988",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.87
      },
      "kind": "metric",
      "text": "Expected cash runway into second half of 2025",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf31b34d-17ca-4663-860d-cffea9278424",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Innovative molecular structures with the potential to overcome the dual challenges of kinase resistance and selectivity in the CNS and in the periphery. Potential for differentiated inhibition of proven kinase targets with opportunities for clinical utility earlier in the treatment paradigm.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "476e1a53-437b-435a-8895-96ef9200935b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.07,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Robust development pipeline leveraging established approach: NVL-330 selected as new development candidate for HER2ex20-positive tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0823ac7-24a9-4e7c-a68f-b8c1e9ee5882",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "title",
      "text": "PRECISELY Targeted Therapies for patients with cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df5b3cf0-81ef-43d6-8c3b-69ee23834d53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "Nuvalent",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9ae8a7f-4f2f-4e44-b4ee-1d84df58a3d8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "42b75005-1ffd-47f7-85f3-a992fb946163",
      "evidence": "summary of key points at the beginning of the presentation",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}